The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting.
Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode.
At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:
Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody, the European Medicines Agency and many more to spur on more efficacious personalised cancer vaccines and cell therapies.
"Great opportunity to learn how to develop and accelerate neoantigen related products not only from speakers but also participants and partners"
Past Attendee, BrightPath Biotherapeutics
“This is the best conference for all the researchers, scientists, investors, business to come together for a better future in the field of neoantigen associated immunotherapy.”
Past Attendee, Abcam